Global Biomarkers Market Overview :
Global Biomarkers market is estimated to reach $103.5 Billion by 2025; growing at a CAGR of 14.3% till 2025. Biomarkers used in clinical research as well as normal research. Biomarkers are computable medical indications to accurately diagnose the precise disease stage. Biomarkers are classified based on disease-related biomarkers and drug-related biomarkers. Impending biomarkers include genomic biomarkers, protein & protein fragments, and cellular biomarkers. It is used to detect particular disease at the early stage possible. Moreover, based on the genetic method, it is classified as type0 (natural history), type1 (drug activity), and type2 (surrogate).
Global Biomarkers Market: Growth Factors
Rising investment in R&D by pharmaceutical companies, growth in cancer patients, and rise in the expenditure of clinical trials by developing countries are fueling the market growth. Moreover, sedentary lifestyle, unhealthy food, and lack of exercise are also driving the growth of the market.
Global Biomarkers Market: Segmentation
The global biomarkers market is mainly segmented on the basis of type and application. On the basis of type; the market is segmented as safety, efficacy, and validation. Based on the application, the market is classified as diagnostic, drug development, personalized medicine, and others. On the basis of disease, the market is divided into cancer, cardiovascular diseases, neurological diseases, immunological diseases, and others.
Global Biomarkers Market: Regional Analysis
On the basis of geography, the market is mainly divided into North America, Europe, Asia-Pacific, and Rest of the World (RoW). North America is further segmented into the U.S., Canada, and Mexico, whereas Europe includes the UK, Germany, France, Italy, and Rest of Europe. Asia-Pacific is categorized as India, China, Japan, South Korea, and Rest of Asia-Pacific, whereas RoW is divided into South America, the Middle East, and Africa.
Global Biomarkers Market: Competitive Players
Key players operating in the market include Perkinelmer, Inc., Qiagen N.V., EKF Diagnostics Holdings, Inc., Merck Millipore, Enzo Biochem, Inc., Meso Scale Diagnostics, LLC, Biosims Technologies Sas, Cisbio Bioassays, Signosis, Inc. and Bio-Rad Laboratories, Inc.
Biomarkers Market Key Segments:
- Drug Development
- Personalized Medicine
- Cardiovascular Diseases
- Neurological Diseases
- Immunological Diseases
- North America
- The U.S.
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Rest of the World
- South America
- Middle East
Key Market Players
- Perkinelmer, Inc.
- Qiagen N.V.
- EKF Diagnostics Holdings, Inc.
- Merck Millipore
- Enzo Biochem, Inc.
- Meso Scale Diagnostics, LLC.
- Biosims Technologies Sas
- Cisbio Bioassays
- Signosis, Inc.
- Bio-Rad Laboratories, Inc.
What Report Provides
- Full in-depth analysis of the parent market
- Important changes in market dynamics
- Segmentation details of the market
- Former, on-going, and projected market analysis in terms of volume and value
- Assessment of niche industry developments
- Market share analysis
- Key strategies of major players
- Emerging segments and regional markets
- Testimonials to companies in order to fortify their foothold in the market